Our Broad and Disruptive Platform

We are delivering a new class of RNA therapies – Antibody Oligonucleotide Conjugates (AOCs). AOCs overcome current barriers to the delivery of oligonucleotides unlocking their potential to treat diseases currently lacking adequate treatment options and allowing us to address unmet patient needs. We have demonstrated preclinical proof of concept for AOCs in multiple tissues. We are broadening our research to other tissue and cell types through internal discovery efforts and partnerships.

Our Advancing and Expanding Pipeline

We are currently progressing a robust pipeline of skeletal muscle programs. Our first program, AOC 1001 has commenced clinical testing with the ongoing Phase 1/2 MARINA trial in adults with myotonic dystrophy type 1 (DM1).

Our next programs, AOC 1044 for people with Duchenne Muscular Dystrophy (DMD) and our AOC FSHD program for people with Facioscapulohumeral Muscular Dystrophy (FSHD), are both on track to enter clinical studies in 2022. By the end of 2022, we plan to have three programs for distinct indications in clinical development.

Beyond the clinical programs, we have research and development efforts focused on skeletal muscle, immune cells and additional cell types. We are driven to accelerate our research to tackle unmet needs and better serve patients and their families.

Our Agile and Diverse Company

Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.

We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.